Vanda urged FDA Commissioner Martin Makary to review the approval of two Hetlioz generics, alleging "bias toward approvals" and citing flawed studies limited to Indian male subjects with inconsistent data. The move follows Vanda's court win reviving its jet lag application. On Stocktwits, retail sentiment for Vanda (VNDA) turned bullish amid high message volume.